Tuesday, April 28, 2026 4:06:02 PM
I don't fear conditional approvals, I just hope that we're not forced into a trial that's identical, or nearly identical, to the Phase 3. We're going to do new trials that should not only say how much more we can do, when our vaccine is combined with other therapeutics, but also how many other solid cancers it can benefit. As long as conditional allows these trials to meet the conditions, I'm fine with them.
I believe an Oncologist worth his salt will add Keytruda, Poly-ICLC, or other similar products to his patient treatment, even if it takes a fight to get it, as the result is so improved in early stage trials. If a new trial fails to include these therapeutics in GBM, why would a patient volunteer for a trial offering 13% survival at 5 years when 50% is possible.
Bashers will find something to criticize as long as the people paying them continue to pay. I suspect some of that money may disappear after approval as some move to the long side as bankrupting the company is no longer possible. No matter what the company does, bashers can always find something to call into question. If someone is paying, they'll be around.
Gary
I believe an Oncologist worth his salt will add Keytruda, Poly-ICLC, or other similar products to his patient treatment, even if it takes a fight to get it, as the result is so improved in early stage trials. If a new trial fails to include these therapeutics in GBM, why would a patient volunteer for a trial offering 13% survival at 5 years when 50% is possible.
Bashers will find something to criticize as long as the people paying them continue to pay. I suspect some of that money may disappear after approval as some move to the long side as bankrupting the company is no longer possible. No matter what the company does, bashers can always find something to call into question. If someone is paying, they'll be around.
Gary
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
